An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients With Osteoarthritis of the Knee

Trial Profile

An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients With Osteoarthritis of the Knee

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Musculoskeletal pain
  • Focus Adverse reactions
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 26 Apr 2018 Results presented in the Flexion Therapeutics media release.
    • 26 Apr 2018 According to a Flexion Therapeutics media release, interim data from this trial will be presented at the Osteoarthritis Research Society International (OARSI) (April 2018) World Congress.
    • 08 Jan 2018 According to a a Flexion Therapeutics media release, full study results are expected in the third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top